drugset / Trial / NCT00411034
A Repeated-Dose Evaluation of Use of a Pain Relieving Drug and Safety of OROS Hydromorphone HCI in Patients With Chronic Cancer Pain
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this repeated dose study is to develop recommended dosing information for initiation of therapy with OROS Hydromorphone HCI (slow release) in patients with chronic cancer pain converting from other strong oral or transdermal opioids. It will also assist in the development of a recommended starting dose by which patients can be titrated to an appropriate maintenance dose of OROS hydromorphone HCI (slow release). The safety profile for OROS Hydromorphone HCI (slow release) will also be evaluated.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 1999-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydromorphone | Other / unclassified | 8 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 16 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 32 mg | Oral |
| Subject | Hydromorphone | Other / unclassified | 64 mg | Oral |
Indications
No indication recorded.